Managing Clinical Trials During COVID-19

Guidance on the Management of Clinical Trials

In Response to the COVID-19 Pandemic

The COVID-19 pandemic has brought about unprecedented challenges, significantly altering the way clinical trials are managed and conducted. Established routines have been disrupted, presenting a series of obstacles such as patients being unable to attend study visits in person, delays in the shipment of medication to trial sites, concerns regarding the stability of study medication, and site monitors and inspectors being unable to perform their essential tasks onsite.

In response to these challenges, the clinical trials industry has adapted by embracing innovative approaches and technologies. Pharmaceutical companies have introduced solutions such as remote-based monitoring, centralised risk-based monitoring, data analytics tools, electronic consent (e-consent), electronic patient-reported outcomes (ePRO) tools, telehealth services, and optional home visits to ensure trial continuity and participant safety. These technologies and methodologies, born out of necessity during the pandemic, have not only maintained the integrity of studies but are likely to shape the future of clinical trials.

Recognising the widespread impact of the pandemic, regulatory authorities such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have provided essential guidance to support the industry, investigators, and patients during this period of disruption. These guidelines offer practical advice on mitigating risks and adapting trial processes to ensure the continuation of essential research.

The EMA's “Guidance on the Management of Clinical Trials During the COVID-19 Pandemic” (version 3, published on 28th April 2020) highlights key considerations for ongoing and future clinical trials. This document emphasises the need for careful evaluation of the pandemic’s impact on various aspects of clinical research, including ongoing trials, the initiation of new trial sites, recruitment efforts, participant involvement, and the launch of new studies. Importantly, it advises that these evaluations must align with national recommendations and the prevailing public health context.

In these extraordinary times, the lessons learned, and innovations developed have underlined the resilience and adaptability of the clinical research community. Remote and digital solutions have demonstrated their effectiveness not only in ensuring patient safety but also in improving accessibility and efficiency. These changes have laid the foundation for a more flexible and patient-centric approach to clinical trials, marking a significant evolution in the field.

As the world continues to navigate the ramifications of the pandemic, the guidance from regulatory authorities and the collaborative efforts of industry stakeholders serve as a testament to the strength and commitment of the clinical research ecosystem. These advancements highlight the importance of innovation, transparency, and global cooperation in overcoming challenges and ensuring the progress of medical science.